SterRx, LLC Issues Voluntary Nationwide Recall of Certain SterRx Products
PLATTSBURGH, N.Y., Nov. 12, 2021 /PRNewswire/ -- SterRx, LLC today announced the voluntary nationwide recall of approximately 240 lots within their expiry period due to equipment and process issues that could lead to a lack of sterility assurance for products intended to be sterile. To date, SterRx, LLC has not received reports of any product complaints or adverse events associated with this issue. SterRx, LLC has initiated this voluntary recall to the hospital pharmacy level out of an abundance of caution.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
The lot numbers being recalled were distributed to hospitals nationwide from December 2020 ? October 2021.
The products impacted are specifically:
1mg/mL Midazolam in 0.9% Sodium Chloride
Fentanyl in 0.9% Sodium Chloride
1mg/mL Morphine Sulfate in 0.9% Sodium Chloride
1mg/mL Morphine Sulfate in 5% Dextrose
125mg Diltiazem HCL in 0.7% Sodium Chloride
125mg Diltiazem HCL in 5% Dextrose
Norepinephrine in 0.9% Sodium Chloride
Norepinephrine in 5% Dextrose
Epinephrine in 0.9% Sodium Chloride
Phenylephrine in 0.9% Sodium Chloride
150mEq Sodium Bicarbonate in 5% Dextrose
200mg Succinylcholine Chloride in 0.9% Sodium Chloride
Product images and lot information is available on www.sterrx.com
Customers are being notified by fax, email, FedEx, and/or certified mail, which includes arrangements for return of all recalled product. Customers have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of, and return as directed the recalled lots of product. The necessary form to document product information, as well as other information regarding this recall, is available at www.sterrx.com.
Customers or healthcare workers with any questions about returning unused product should be directed to the customer call center at (518) 324-7983 M-F 8:00am to 5:00pm EST or email [email protected]. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Regular Mail or Fax: Download form www.fda.gov/medwatch or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
CUSTOMER SUPPORT: Customer Call Center (518) 324-7983
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...
FIRST QUARTER (JANUARY - MARCH 2024)
Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...